cefazedone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 3071 56187-47-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefazedone sodium
  • EMD30087
  • cefazedone
  • refosporen
  • Molecular weight: 548.43
  • Formula: C18H15Cl2N5O5S3
  • CLOGP: -0.65
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 2
  • TPSA: 132.80
  • ALOGS: -4.85
  • ROTB: 7

Drug dosage:

DoseUnitRoute
3 g P

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.13 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.95 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.91 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.908 Moderate 0.73
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.678 Moderate 0.73
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.700 10^-6 cm/s Moderate 0.73
dh-clint Dog hepatocyte intrinsic clearance 1.262 uL/min/10^6 cells Moderate 0.73
dppb Dog plasma protein binding (% unbound) 59.830 % Moderate 0.73
fcs-ppb Fetal calf serum protein binding (% unbound) 43.590 % Moderate 0.73
herg hERG pIC50 4.411 pIC50 Moderate 0.73
hh-clint Human hepatocyte intrinsic clearance 1.968 uL/min/10^6 cells Moderate 0.73
hlm-clint Human liver microsomal intrinsic clearance 4.285 uL/min/mg protein Moderate 0.73
hppb Human plasma protein binding (% unbound) 33.490 % Moderate 0.73
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TTK,ZAP70 41
kinase-selectivity-class AXL,BRAF,CDK9,EIF2AK3,GRK2,MAP2K6,MAPK7,PRKDC,STK33,TEK,TTK 11
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.889 Moderate 0.73
mh-clint Mouse hepatocyte intrinsic clearance 2.328 Moderate 0.73
mppb Mouse plasma protein binding (% unbound) 47.470 Moderate 0.73
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.219 Moderate 0.73
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 28.570 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 1.114 uL/min/10^6 cells Moderate 0.73
rh-fuinc Rat hepatocyte fraction unbound in incubation 88.230 % Moderate 0.73
rppb Rat plasma protein binding (% unbound) 25.530 % Moderate 0.73
solubility-dd Solubility at pH 7.4 in DMSO 984.011 uM Moderate 0.73

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DB06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
First-generation cephalosporins
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:36047 antibacterial drug

Related Drugs by ATC class:

J01DB First-generation cephalosporins 11 drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.22 acidic
pKa2 1.52 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D07237 KEGG_DRUG
63521-15-3 SECONDARY_CAS_RN
C0054999 UMLSCUI
CHEBI:131731 CHEBI
CHEMBL2107636 ChEMBL_ID
DB13778 DRUGBANK_ID
C021341 MESH_SUPPLEMENTAL_RECORD_UI
12203 IUPHAR_LIGAND_ID
4117 INN_ID
7Y86X0D799 UNII
71736 PUBCHEM_CID
010926 NDDF
010927 NDDF

Pharmaceutical products:

None